Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
Immunotherapy|April 21, 2026
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabAli Kaan Güren, Nazım Can Demircan, Özge Gümüşay, et al.
BMC Cancer|December 30, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective studySeda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, et al.
Journal of Cancer Research and Clinical Oncology|June 10, 2022
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology GroupMustafa Gürbüz, Yasin Kutlu, Erman Akkuş, et al.
Frontiers in Immunology|December 26, 2025
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter studyTaha Koray Sahin, Fatih Atalah, Bahadir Koylu, et al.
Journal of Chemotherapy (Florence, Italy)|January 24, 2024
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencingOsman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 6, 2026
Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort studyCarlotta Becherini, Eva Blondeaux, Virginia Delucchi, et al.
Therapeutic Advances in Medical Oncology|March 16, 2026
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter studyTaha Koray Sahin, Fatih Kemik, Harun Muglu, et al.
Journal of Clinical Medicine|February 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective AnalysisBaris Koksal, Hasan Cagri Yildirim, Deniz Can Guven, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudyMustafa Seyyar, Ali Kalem, Mürsel Sali, et al.
The Oncologist|September 7, 2023
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology GroupÇağlar Ünal, Abdulmunir Azizy, Senem Karabulut, et al.
Pageof 20